Docetaxel, oxaliplatin and S-1 in neoadjuvant chemotherapy of markers, angiogenesis and cell invasion of advanced gastric cancer patients with tumor molecular

摘要

Objective: To investigate the effect of neoadjuvant chemotherapy of docetaxel, oxaliplatin and S-1 for advanced gastric cancer patients with tumor markers, vascular invasion and cell molecular level in newborn. Methods: A total of 84 patients with advanced gastric cancer were randomly divided into control group (n=42) and observation group (n=42) according to the random data table method, patients in the control group were treated with docetaxel, oxaliplatin and fluorouracil chemotherapy, and patients in the observation group were given neoadjuvant chemotherapy with docetaxel, oxaliplatin and S-1, the levels of tumor markers, angiogenesis and cell invasion molecules of the two groups before and after treatment (3 cycles after chemotherapy) were compared. Results: there was no significant difference in the levels of CEA, CA19-9, VEGF, IGF-1, MMP-2 and MMP-9 between the two groups before treatment;After treatment, two groups of CEA, CA19-9, VEGF, IGF-1, MMP-2 and MMP-9 were significantly lower than those in the same group before treatment, and the observation group [(5.71±1.72) ng/mL, (16.31±3.17) U/mL, (136.89±17.93) ng/L, (215.26±29.05) g/L, (59.87±8.93) ng/mL, (198.97±67.21) ng/mL] was significantly lower than the control group [(11.92±2.61) ng/mL, (28.65±3.93) U/mL, (202.73±21.86) ng/L, (303.47±36.03) g/L, (82.68±10.49) ng/mL, (291.78±94.06) ng/mL], the difference was statistically significant. Conclusion: Neoadjuvant chemotherapy of docetaxel, oxaliplatin and S-1 for advanced gastric cancer can effectively reduce serum tumor marker levels, inhibition of vascular invasion and cell growth factor release level, has important clinical value.